EMEA-002387-PIP02-21

Table of contents

Key facts

Invented name
Nexpovio
Active substance
Selinexor
Therapeutic area
Oncology
Decision number
P/0364/2021
PIP number
EMEA-002387-PIP02-21
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of endometrial carcinoma
Route(s) of administration
Oral use
Contact for public enquiries
Karyopharm Europe GmbH

E-mail: cnippgen@karyopharm.com
Tel: +4915118568262

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating